The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Selecting BCMA-directed immunotherapies after 1-3 prior lines in multiple myeloma
Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, discusses factors influencing the selection of BCMA-directed immunotherapies for patients with multiple myeloma following 1-3 prior lines of therapy. Dr Hansen highlights disease biology, patient fitness, and logistical considerations as key drivers of treatment selection, emphasizing the importance of shared decision-making to align treatment with patients’ goals, circumstances, and lifestyle. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
